Structural myocardial alterations in diabetes and hypertension: The role of galectin-3

Clinical Chemistry and Laboratory Medicine

Volumn 52, Issue 10, 2014, Pages 1499-1505

  Seferovic, Jelena P ^a   Lalic, Nebojsa M ^a   Floridi, Federico ^b   Tesic, Milorad ^c   Seferovic, Petar M ^c   Giga, Vojislav ^a,c   Lalic, Katarina ^d,e   Jotic, Aleksandra ^d,e   Jovicic, Snezana ^b,f   Colak, Emina ^f   Salerno, Gerardo ^d   Cardelli, Patrizia ^b   Di Somma, Salvatore ^f  

^a CLINICAL CENTER OF SERBIA   (Serbia)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF BELGRADE   (Serbia)

^d UNIVERSITY OF BELGRADE   (Serbia)

^e Center for Medical Biochemistry   (Serbia)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Galectin 3; Hypertension; Myocardial fibrosis; Type 2 diabetes

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; GALECTIN 3;

ADULT; ARTICLE; CORONARY ARTERY DISEASE; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE MASS; HEART MUSCLE FIBROSIS; HUMAN; HYPERTENSION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROTEIN FUNCTION; STRESS ECHOCARDIOGRAPHY; TISSUE DOPPLER IMAGING; DIABETES MELLITUS, TYPE 2; ELECTROCARDIOGRAPHY; HEART MUSCLE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY;

DIABETES MELLITUS, TYPE 2; ELECTROCARDIOGRAPHY; FEMALE; GALECTIN 3; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MYOCARDIUM;

EID: 84921353607     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2014-0265     Document Type: Article

References (21)

1. Rabinovich GA, Rubinstein N, Toscano MA. Role of galectins in inflammatory and immunomodulatory processes. Biochim Biophys Acta 2002;1572:274-84.
2. de Boer RA, van Veldhuisen DJ, Gansevoort RT, Muller Kobold AC, van Gilst WH, Hillege HL, et al. The fibrosis marker galectin-3 and outcome in the general population. J Intern Med 2012;272:55-64.
3. de Boer RA, Voors AA, Muntendam P, van Gilst WH, van Veldhuisen DJ. Galectin-3: a novel mediator of heart failure development and progression. Eur J Heart Fail 2009;11:811-7.
4. Weigert J, Neumeier M, Wanninger J, Bauer S, Farkas S, Scherer MN, et al. Serum galectin-3 is elevated in obesity and negatively correlates with glycosylated hemoglobin in type 2 diabetes. J Clin Endocrinol Metab 2010;95:1404-11.
5. Iacobini C, Amadio L, Oddi G, Ricci C, Barsotti P, Missori S, et al. Role of galectin-3 in diabetic nephropathy. J Am Soc Nephrol 2003;14:S264-70.
6. Mensah-Brown EP, Al Rabesi Z, Shahin A, Al Shamsi M, Arsenijevic N, Hsu DK, et al. Targeted disruption of the galectin-3 gene results in decreased susceptibility to multiple low dose streptozotocin- induced diabetes in mice. Clin Immunol 2009;130:83-8.
7. Nachtigal M, Ghaffar A, Mayer EP. Galectin-3 gene inactivation reduces atherosclerotic lesions and adventitial inflammation in ApoE-deficient mice. Am J Pathol 2008;172:247-55.
8. Henderson NC, Sethi T. The regulation of inflammation by galectin-3. Immunol Rev 2009;230:160-71.
9. Levey AS, Coresh J, Greene T, Marsh J, Stevens LA, Kusek JW, et al. Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem 2007;53:766-72.
10. Teichholz LE, Kreulen T, Herman MV, Gorlin R. Problems in echocardiographic volume determinations: echocardiographic-angiographic correlations in the presence of absence of asynergy. Am J Cardiol 1976;37:7-11.
11. Paulus WJ, Tschope C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE, et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007;28:2539-50.
12. Bruce RA. Exercise testing of patients with coronary heart disease. Principles and normal standards for evaluation. Ann Clin Res 1971;3:323-32.
13. Yang RY, Rabinovich GA, Liu FT. Galectins: structure, function and therapeutic potential. Expert Rev Mol Med 2008;10:e17.
14. Ronco C, McCullough P, Anker SD, Anand I, Aspromonte N, Bagshaw SM, et al. Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative. Eur Heart J 2009;31:703-11.
15. Lok DJ, Van Der Meer P, de la Porte PW, Lipsic E, Van Wijngaarden J, Hillege HL, et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol 2010;99:323-8.
16. Karayannis G, Triposkiadis F, Skoularigis J, Georgoulias P, Butler J, Giamouzis G. The emerging role of galectin-3 and ST2 in heart failure: practical considerations and pitfalls using novel biomarkers. Curr Heart Fail Rep 2013;10:441-9.
17. Rytter E, Vessby B, Asgard R, Johansson C, Sjodin A, Abramsson- Zetterberg L, et al. Glycaemic status in relation to oxidative stress and inflammation in well-controlled type 2 diabetes subjects. Br J Nutr 2009;101:1423-6.
18. Jin QH, Lou YF, Li TL, Chen HH, Liu Q, He XJ. Serum galectin-3: a risk factor for vascular complications in type 2 diabetes mellitus. Chin Med (Engl) 2013;126:2109-15.
19. De Boer RA, Pinto YM, Van Veldhuisen DJ. The imbalance between oxygen demand and supply as a potential mechanism in the pathophysiology of heart failure: the role of microvascular growth and abnormalities. Microcirculation 2003;10:113-26.
20. Calvier L, Miana M, Reboul P, Cachofeiro V, Martinez-Martinez E, de Boer RA, et al. Galectin-3 mediates aldosterone-induced vascular fibrosis. Arterioscler Thromb Vasc Biol 2013;33:67-75.
21. Ochieng J, Furtak V, Lukyanov P. Extracellular functions of galectin-3. Glycoconj J 2004;19:527-35.